for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

日本たばこ産業株式会社

2914.T

現在値

2,798.00JPY

変化

-40.50(-1.43%)

出来高

10,753,400

本日のレンジ

2,792.00

 - 

2,875.50

52週レンジ

2,072.00

 - 

2,875.50

∙ 約20分前の相場を表示しています。

適時開示

Juul Explores Potential Sale, Investment Or Distribution Deal With Philip Morris, Japan Tobacco Or Altria - WSJ

Jan 25 (Reuters) - :JUUL EXPLORES POTENTIAL SALE, INVESTMENT OR DISTRIBUTION DEAL WITH PHILIP MORRIS, JAPAN TOBACCO OR ALTRIA - WSJ.

Japan Tobacco - To Promote Senior Vice President Kei Nakano As Executive Vice President Effective Jan. 1

Nov 25 (Reuters) - Japan Tobacco Inc <2914.T>::* TO PROMOTE SENIOR VICE PRESIDENT KEI NAKANO AS EXECUTIVE VICE PRESIDENT EFFECTIVE JAN. 1.Further company coverage: [2914.t]. (Tokyo Newsroom).

Altria Announces Strategic Partnership With Jt Group And Expanded Heated Tobacco Portfolio

Oct 27 (Reuters) - Altria Group Inc <MO.N>::ALTRIA ANNOUNCES STRATEGIC PARTNERSHIP WITH JT GROUP AND EXPANDED HEATED TOBACCO PORTFOLIO.ALTRIA GROUP INC - CO AND JT GROUP ANNOUNCE JOINT VENTURE FOR U.S. MARKETING AND COMMERCIALIZATION OF HEATED TOBACCO STICK PRODUCTS.ALTRIA GROUP INC - PM USA ENTERED INTO JV WITH SUBSIDIARY OF JT, JAPAN TOBACCO INTERNATIONAL FOR U.S. MARKETING AND COMMERCIALIZATION OF HTS PRODUCTS.ALTRIA GROUP - JV IS STRUCTURED TO EXIST IN PERPETUITY AND ESTABLISHES HORIZON INNOVATIONS LLC.ALTRIA GROUP INC - PM USA HOLDS A 75% ECONOMIC INTEREST IN HORIZON, WITH JTI HAVING A 25% ECONOMIC INTEREST.ALTRIA GROUP - PARTIES EXPECT TO COMBINE SCIENTIFIC AND REGULATORY EXPERTISE TO JOINTLY PREPARE FDA FILINGS FOR LATEST VERSION OF PLOOM HTS PRODUCTS.ALTRIA GROUP INC - PARTIES CURRENTLY EXPECT TO SUBMIT PRE-MARKET TOBACCO PRODUCT APPLICATIONS (PMTA) FOR THESE PRODUCTS IN FIRST HALF OF 2025.ALTRIA GROUP INC - UPON PMTA AUTHORIZATIONS, HORIZON WILL BECOME EXCLUSIVE ENTITY THROUGH WHICH PARTIES MARKET AND COMMERCIALIZE HTS PRODUCTS IN U.S..ALTRIA GROUP INC - JTI WILL SUPPLY PLOOM HTS DEVICES AND PM USA WILL MANUFACTURE MARLBORO HTS CONSUMABLES FOR U.S. COMMERCIALIZATION.

FDA Denies Marketing Of Logic’S Menthol E-Cigarette Products Following Determination They Do Not Meet Public Health Standard

Oct 26 (Reuters) - FDA ::FDA DENIES MARKETING OF LOGIC’S MENTHOL E-CIGARETTE PRODUCTS FOLLOWING DETERMINATION THEY DO NOT MEET PUBLIC HEALTH STANDARD.FDA - ISSUED MARKETING DENIAL ORDERS (MDOS) FOR SEVERAL E-CIGARETTE PRODUCTS CURRENTLY MARKETED BY LOGIC TECHNOLOGY DEVELOPMENT LLC (LOGIC). ((Reuters.Briefs@thomsonreuters.com;)).

Japan Tobacco Inc - JT International Financial Services B.V. To Issue $500 Million In 10-Year Bonds

Oct 20 (Reuters) - Japan Tobacco Inc <2914.T>::JT INTERNATIONAL FINANCIAL SERVICES B.V. TO ISSUE $500 MILLION IN 10-YEAR BONDS.

Japan Tobacco Applied To Japan Ministry Of Finance To Raise Tobacco Retail Prices

Aug 25 (Reuters) - Japan Tobacco Inc <2914.T>::JAPAN TOBACCO: APPLIED TO JAPAN MINISTRY OF FINANCE TO RAISE TOBACCO RETAIL PRICES.Further company coverage: 2914.T. (Reporting by Sakura Murakami). ((Sakura.Murakami@thomsonreuters.com;)).

Japan Tobaccco Group Announces New Operating Model As Company Aims To Strengthen Its Tobacco Business

Feb 9 (Reuters) - Japan Tobacco Inc <2914.T>::GROUP ANNOUNCES NEW OPERATING MODEL AS COMPANY AIMS TO STRENGTHEN ITS TOBACCO BUSINESS.TO CONSOLIDATE CURRENT INTERNATIONAL AND JAPANESE-DOMESTIC TOBACCO BUSINESSES INTO ONE TOBACCO BUSINESS.TO OFFER VOLUNTARY RETIREMENT PROGRAMME AND SEEK RETIREMENT OF ABOUT 1,000 EMPLOYEES.

Japan Tobacco To Sell Tokyo Tower Building To Sumitomo Realty - Nikkei, Citing Sources

Oct 15 (Reuters) - Nikkei::JAPAN TOBACCO INC TO SELL ITS 35-STORY TOKYO TOWER BUILDING TO SUMITOMO REALTY & DEVELOPMENT - NIKKEI, CITING SOURCES.

Japan Tobacco Inc - Transfer Date Of Marketing Approvals Of 6 Anti-Hiv Drugs To Gilead Sciences Kk Set For Dec. 1

Japan Tobacco Inc <2914.T>::JAPAN TOBACCO INC - TRANSFER DATE OF MARKETING APPROVALS OF 6 ANTI-HIV DRUGS TO GILEAD SCIENCES KK SET FOR DEC. 1.

Japan Tobacco Top-Line Results Of Phase 3 Clinical Studies Of JTZ-951 In Anemic Patients With Chronic Kidney Disease In Japan

July 12 (Reuters) - Japan Tobacco Inc <2914.T>::TOP-LINE RESULTS OF PHASE 3 CLINICAL STUDIES OF JTZ-951 IN ANEMIC PATIENTS WITH CHRONIC KIDNEY DISEASE IN JAPAN.RESULTS SHOW BOTH STUDIES MET PRIMARY ENDPOINTS.JT AND TORII <<<4551.T>>> WILL AIM TO SUBMIT MARKETING APPLICATION FOR JTZ-951 IN JAPAN BASED ON RESULTS OF THIS AND OTHER CLINICAL STUDIES.

金融情報はリフィニティブから。すべての情報は少なくとも20分遅れで表示されています。

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up